Cognition Therapeutics, Inc. Operating Expenses
Cognition Therapeutics, Inc. (CGTX) reported Operating Expenses of $7.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-07
- Cognition Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $7.74M, a 44.64% decline year-over-year.
- Cognition Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $8.82M, a 35.99% decline year-over-year.
- Cognition Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $13.67M, a 27.49% increase year-over-year.
- Cognition Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $6.38M, a 55.92% decline year-over-year.
- Cognition Therapeutics, Inc. operating expenses for fiscal 2025 was $47.80M, a 11.43% decline from fiscal 2024.
- Cognition Therapeutics, Inc. operating expenses for fiscal 2024 was $53.97M, a 6.39% increase from fiscal 2023.
- Cognition Therapeutics, Inc. operating expenses for fiscal 2023 was $50.72M, a 16.47% increase from fiscal 2022.
- Cognition Therapeutics, Inc. operating expenses for fiscal 2022 was $43.55M, a 52.29% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.74M 10-Q · filed 2026-08-07 | $16.55M 10-Q · filed 2026-08-07 | $30.23M derived: sum of 3 quarters · filed 2026-08-07 | $36.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $8.82M 10-Q · filed 2026-05-08 | $22.49M derived: sum of 2 quarters · filed 2026-05-08 | $28.86M derived: sum of 3 quarters · filed 2026-05-08 | $42.84M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $13.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $20.05M derived: sum of 2 quarters · filed 2026-03-26 | $34.02M derived: sum of 3 quarters · filed 2026-08-07 | $47.80M 10-K · filed 2026-03-26 |
| 2025-09-30 | $6.38M 10-Q · filed 2025-11-06 | $20.35M derived: sum of 2 quarters · filed 2026-08-07 | $34.13M 10-Q · filed 2025-11-06 | $44.85M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $13.98M 10-Q · filed 2026-08-07 | $27.75M 10-Q · filed 2026-08-07 | $38.48M derived: sum of 3 quarters · filed 2026-08-07 | $52.94M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $13.78M 10-Q · filed 2026-05-08 | $24.50M derived: sum of 2 quarters · filed 2026-05-08 | $38.96M derived: sum of 3 quarters · filed 2026-05-08 | $53.64M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $10.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $25.19M derived: sum of 2 quarters · filed 2026-03-26 | $39.86M derived: sum of 3 quarters · filed 2026-03-26 | $53.97M 10-K · filed 2026-03-26 |
| 2024-09-30 | $14.46M 10-Q · filed 2025-11-06 | $29.14M derived: sum of 2 quarters · filed 2025-11-06 | $43.24M 10-Q · filed 2025-11-06 | $58.43M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $14.68M 10-Q · filed 2025-08-07 | $28.78M 10-Q · filed 2025-08-07 | $43.97M derived: sum of 3 quarters · filed 2025-08-07 | $58.71M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $14.10M 10-Q · filed 2025-05-07 | $29.29M derived: sum of 2 quarters · filed 2025-05-07 | $44.04M derived: sum of 3 quarters · filed 2025-05-07 | $55.85M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $15.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $29.93M derived: sum of 2 quarters · filed 2025-03-20 | $41.75M derived: sum of 3 quarters · filed 2025-03-20 | $50.72M 10-K · filed 2025-03-20 |
| 2023-09-30 | $14.74M 10-Q · filed 2024-11-13 | $26.56M derived: sum of 2 quarters · filed 2024-11-13 | $35.53M 10-Q · filed 2024-11-13 | $44.84M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $11.82M 10-Q · filed 2024-08-08 | $20.79M 10-Q · filed 2024-08-08 | $30.09M derived: sum of 3 quarters · filed 2024-08-08 | $42.72M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $8.97M 10-Q · filed 2024-05-07 | $18.27M derived: sum of 2 quarters · filed 2024-05-07 | $30.90M derived: sum of 3 quarters · filed 2024-05-07 | $43.11M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $21.93M derived: sum of 2 quarters · filed 2024-03-26 | $34.14M derived: sum of 3 quarters · filed 2024-03-26 | $43.55M 10-K · filed 2024-03-26 |
| 2022-09-30 | $12.63M 10-Q · filed 2023-11-02 | $24.84M derived: sum of 2 quarters · filed 2023-11-02 | $34.25M 10-Q · filed 2023-11-02 | $46.06M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $12.21M 10-Q · filed 2023-08-08 | $21.63M 10-Q · filed 2023-08-08 | $33.43M derived: sum of 3 quarters · filed 2023-08-08 | $38.66M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $9.41M 10-Q · filed 2023-05-04 | $21.22M derived: sum of 2 quarters · filed 2023-05-04 | $26.44M derived: sum of 3 quarters · filed 2023-05-04 | $32.43M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $11.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $17.03M derived: sum of 2 quarters · filed 2023-03-23 | $23.02M derived: sum of 3 quarters · filed 2023-03-23 | $28.60M 10-K · filed 2023-03-23 |
| 2021-09-30 | $5.22M 10-Q · filed 2022-11-14 | $11.21M derived: sum of 2 quarters · filed 2022-11-14 | $16.79M 10-Q · filed 2022-11-14 | $20.91M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $5.98M 10-Q · filed 2022-08-09 | $11.57M 10-Q · filed 2022-08-09 | $15.69M derived: sum of 3 quarters · filed 2022-08-09 | $20.15M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $5.58M 10-Q · filed 2022-05-11 | $9.70M derived: sum of 2 quarters · filed 2022-05-11 | $14.16M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $8.58M derived: sum of 2 quarters · filed 2022-03-30 | $17.41M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $4.46M 10-Q · filed 2021-11-17 | $13.29M 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |